Why did p53 gene therapy fail in ovarian cancer?

Lancet Oncology

Volumn 4, Issue 7, 2003, Pages 415-422

  Zeimet, Alain G ^a   Marth, Christian ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; INTEGRIN RECEPTOR; NAVELBINE; NEUTRALIZING ANTIBODY; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; PROTEIN P63; PROTEIN P73; VIRUS RECEPTOR;

ASCITES; CANCER RESEARCH; CELL HETEROGENEITY; CLINICAL TRIAL; COXSACKIE VIRUS; DNA SPLICING; DRUG EFFICACY; FEMALE; GENE INTERACTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC IDENTIFICATION; GENETIC REGULATION; GENETIC VARIABILITY; HUMAN; NONHUMAN; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TARGET CELL; TRANSGENE; TREATMENT FAILURE; TUMOR CELL; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE;

EID: 0037627875     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01139-2     Document Type: Review

References (73)

1. Zeimet AG, Riha K, Berger J, at al. New insights into p53 regulation and gene therapy for cancer. Biochem Pharmacol 2000; 60: 1153-63.
2. Runnebaum IB. Intraperitioneale p53-gentherapie des ovarialkarzinoms in der klinischen prüfung interimsanalyse eines vielversprechenden ansatzes zur "kausalen" therapie. Arch Gynecol Obstet 1999; 263: 166-68.
3. Buller RE, Runnebaum IB, Karlan BY, et al. A phaseI/II trial of rAD/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Therapy 2002; 9: 553-66.
4. Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor supressor genes involved in epithelial ovarian cancer. Int J Oncol 2000; 16: 567-76.
5. Maxwell SA, Davis GE. Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis sensitive tumor cells. Proc Natl Acad Sci 2000; 97: 13009-14.
6. Liu JR, Opipari AW, Tan L, et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002; 62: 924-31.
7. Jones PA. DNA methylation errors and cancer. Cancer Res 1996; 56: 2463-67.
8. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-174.
9. Widschwendter M, Berger J, Müller HM, et al. Epigenetic downregulation of the retinoic acid receptor-β2 gene in breast cancer. J Mammar Gland Biol Neopl 2001; 6: 193-201.
10. Lu AP, Gupta A, Li C, et al. Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences. Oncogene 2001; 20: 5173-85.
11. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-11.
12. Wolf BB, Schuler M, Li W, et al. Defective cytochrome c-dependent caspace activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem 2001; 276: 34244-51.
13. Ono K, Tanaka T, Tsunoda T, et al. Identification by c-DNA microarray of genes involved in ovarian carcinogeneis. Cancer Res 2000; 60: 5007-11.
14. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-64.
15. Kigawa J, Sato S, Shimada M, et al. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001; 14: 165-71.
16. Reles A, Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 2984-97.
17. Brown JM, Wouters BG. Apoptosis, p53 and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-99.
18. Vousden KH. p53: death star. Cell 2000; 103: 691-94.
19. Vousden KH. Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 2002; 1602: 47-59.
20. Lu YJ, Yamagishi N, Yagi T, Takebe H. Mutated p21WAF1/CIP1/SDI1 lacking CDK inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene 1998; 16: 705-12.
21. Gorospe M, Cirielli C, Wang XT, et al. p21WAF1/CIP1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997; 14: 929-35.
22. Wang Y. Blandino G, Givol D. Induced p21WAF1 expression in H1299 cell line promotes cell scenescence and protects against cytotoxic effects of radiation and doxurubicin. Oncogene 1999; 18: 2643-49
23. Seoane J, Le HV, Massagué J. Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419: 729-34.
24. Vousden KH. Switching from life to death: The Miz-ing link between Myc and p53. Cancer Cell 2002; 2: 351-52.
25. Komarowa EA, Gudkov AV. Suppression of p53: a new approach to overcome side effects of antitumor therapy. Biochemistry 2000; 65: 41-48.
26. Shimada M, Kigawa J, Kanamori Y, et al. Mechanisms of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts. Eur J Cancer 2000; 36: 1869-75.
27. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the response to therapeutic agents. J Clin Invest 1999; 104: 263-69
28. Zamble DB, Jacks T, Lippard SJ. p53-dependent and independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci USA 1998; 95: 6163-68.
29. Pestell KE, Hobbs SM, Titley JC, et al. Effects of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 2000; 57: 503-11.
30. Schuler M, Herrmann R, DeGreve JL, et al. Adenovirus-mediated wild-type p53 gene transfer patients receiving chemo-therapy for advanced non-small cell lung cancer: results of a multicenter phase II study, J Clin Oncol 2001; 19: 1750-58.
31. Swicher SG, Roth JA. p53 Gene therapy for lung cancer. Curr Oncol Rep 2002; 4: 334-40.
32. Swisher SG, Roth JA, Carbone DP. Genetic and immunologic therapies for lung cancer. Semin Oncol 2002; 29 (suppl): 95-101.
33. Chen PL, Chen Y, Bookstein R. Lee WH. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576-80.
34. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345-47.
35. Frebourg T, Sadelein M, Ng YS, et al. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res 1994; 54: 878-81.
36. Monti P, Campomenosi P, Ciribilli Y, et al. Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene 2002; 21: 1641-48.
37. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homology at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-16.
38. Pozniak CD, Radinovic S, Yang A, et al. An anti-apoptotic role for the p53 family member, p53, during developmental neuron death. Science 2000; 289: 304-06
39. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404: 99-103.
40. Ng SW, Yiu GK, Liu Y, et al. Analysis of p73 in human borderline and invasive ovarian tumors. Oncogene 2000; 19: 1885-90.
41. Von Grueningen VE, Santoso JT, Coleman RL, et al. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer. Gynecol Oncol 1998; 69: 197-20.
42. Kigawa J, Sato S, Shimada M, et al. Effects of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells. Gynecol Oncol 2002; 84: 210-15.
43. Stevenson SC, Rollence M, White B, et al. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol 1995; 69: 2850-57.
44. Wickham TJ, Mathias P, Cheresch DA, Nemerow GR. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-19.
45. Sewell DA, Li D, Duan L, et al. Optimizing suicide gene therapy for head and neck cancer. Laryngoscope 1997; 107: 1490-95.
46. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-23.
47. Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325-30.
48. Zeimet AG, Müller-Holzner E, Schuler A, et al. Determination of molecules regulating gene delivery using adenoviral in ovarian carcinomas. Gene Ther 2002; 9: 1093-100.
49. Bruning A, Kohler T, Quist S, et al. Adenoviral transduction efficiency of ovarian cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. Hum Gene Ther 2001; 12: 391-99.
50. Li E, Brown SL, Stupack DG, et al. Integrin αvβ1 is an adenovirus coreceptor. J Virol 2001; 75: 5405-09.
51. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-13.
52. Hemminki A, Zinn KR, Liu B, et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst 2002; 94: 741-49.
53. Kelly FJ, Miller CR, Buchsbaum DJ, et al. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin Cancer Res 2000; 6: 4323-33.
54. Miller RM, Buschbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738-48.
55. Goldman CK, Rogers, BE, Douglas JT, et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997; 57: 1447-51.
56. Stallwood Y, Fisher KD, Gallimore PH, Mautner V. Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients. Gene Ther 2000; 7: 637-43.
57. Thoelen I, Magnusson C, Tagerud S, et al. Identification of alternative splice products encoded by the human coxsackie-adenovirus receptor gene. Biochem Biophys Res Comm 2001; 287: 216-22.
58. Kim J, Hwang ES, Kim JS, et al. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. Cancer Gene Ther 1999; 6: 172-78.
59. Casado E, Gomez-Navarro J, Yamamoto M, et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001; 7: 2496-504.
60. Pujade-Lauraine E, Guastalla JP, Colombo N, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy. J Clin Oncol 1996; 14: 343-50.
61. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engle J Med 1996; 335: 1950-55.
62. Stoiber H, Pinter C, Siccardi AG, et al. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J. Exp Med 1996; 183: 307-10.
63. Yang Y, Jooss KU, Su Q, et al. Immune response to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996; 3: 137-44.
64. Nielsen LL, Dell J, Maxwell E, et al. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 1997; 4: 129-38.
65. Burgert HG, Ruzsics Z, Obermeier S, et al. Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 2002; 269: 273-318.
66. Qin L, Ding Y, Pahud DR, et al. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-29.
67. Hwang ES, Kim J, Kim JS, et al. The effects of the adenovirus-mediated wild-type p53 delivery in human epithelial ovarian cancer cell line in vitro and in vivo. Int J Genecol Cancer 1998; 8: 27-36.
68. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-80.
69. Breyer B, Jiang W, Cheng H et al. Adenoviral vector mediated gene transfer for human gene therapy. Curr Gene Ther 2001; 1: 149-62.
70. Tai Y, Strobel t, Kufe D, Cannistra S. In vivo cytotoxicity of ovarian cancer cells through selective Bax gene. Cancer Res 1999; 59: 2121-26.
71. Ring C, Blouin P, Martin L, et al. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumor selective expression fo a prodrug activating enzyme. Gene Ther 1997; 4: 1045-52.
72. Ichige K, Perey K, Vogel C, et al. Expression of the DF3-P epitope in human ovarian carcinomas. Clin Cancer Res 1995; 1: 565-71.
73. Casado E, Nettelbeck DM, Gomez-Navarro J, et al. Transcriptional targeting for ovarian cancer gene therapy. Gynecol Oncol 2001; 82: 229-37.